SCIN

Across TCGA pan-cancer cohorts, SCIN mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SCIN data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SCIN mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SCIN expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, COAD, and LUAD are the cancer types where SCIN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.627	0.427	.006	26	view →
COAD	DFS	Tertile	II,III,IV	1.000	0.865	.028	24	view →
LUAD	DFS	Tertile	All	0.484	0.825	.001	19	view →
GBM	OS	Tertile	All	0.349	0.653	.001	12	view →
CCRCC	DFS	Quartile	III,IV	0.140	0.830	.038	6	view →
LSCC	DFS	Median	All	0.892	1.000	.024	3	view →
HNSC	OS	Quartile	IV	0.878	0.560	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SCIN–PDAC (OS)

Open the PDAC breakdown →